Mankind Pharma News and Updates

Name: Latest research reports of Mankind Pharma Ltd. authored by Geojit BNP Paribas and published by - Trendlyne research reports.
Item: Mankind Pharma Ltd.
Rating: 5
Author: Geojit BNP Paribas

Keep track of all breaking news on Mankind Pharma from all sources in a single place.

Mankind Pharma Ltd.

26 Nov 2025

2166.80

0.83%

MANKIND PHARMA LIMITED

Buy: Mankind Pharma Ltd.

Recommendation Target

Geojit BNP Paribas

*over or under performance to benchmark index Mankind Pharma is an Indian multinational pharmaceutical and healthcare product company, headquartered in New Delhi. The company has products in therapeutic areas...

Mankind Pharma Ltd. is trading below all available SMAs

Mankind Pharma Ltd.

07 Nov 2025

2166.80

0.83%

Jefferies Keeps Mankind Pharma Among Top Picks Despite Q2 Setback Check Revised Target Price

NDTV Profit

Jefferies has trimmed the target price of Mankind Pharma citing a slower-than-expected recovery in its reorganisation efforts.

Number of FII/FPI investors decreased from 648 to 627 in Sep 2025 qtr

Mankind Pharma Q2 PAT drops 21% on high finance costs; revenue up 20%

Business Standard | 06 Nov 2025

Mankind Pharma Ltd.

07 Nov 2025

2166.80

0.83%

2Q in line; transition phase underway

Buy: Mankind Pharma Ltd.

Target

Motilal Oswal

Mankind Pharma (MANKIND) delivered a largely in-line financial performance for 2QFY26. EBITDA was slightly lower than estimates due to higher employee costs.

Mankind Pharma Ltd. has an average target of 2700.00 from 2 brokers.

Mankind Pharma Ltd.

06 Nov 2025

2166.80

0.83%

Mankind Pharma Results Earnings Call for Q2FY26

Conference Call with Mankind Pharma Management and Analysts on Q2FY26 Performance and Outlook. Listen to the full earnings transcript.

audio

Mankind Pharma Ltd.

06 Nov 2025

2166.80

0.83%

to see Rapid results content

Mankind Pharma Ltd.

06 Oct 2025

2166.80

0.83%

Pharma tariffs and value retailers: Sudip Bandyopadhyay shares market outlook

Economic Times

Sudip Bandyopadhyay advises caution in pharma due to US tariff uncertainties, recommending domestic-focused companies like Mankind Pharma for growth. He also anticipates a strong Q3 for value retailers, including V-Mart, driven by rising incomes and festive demand. Overall, domestic sectors offer safer growth amidst global volatility.

Geojit BNP Paribas upgraded Mankind Pharma Ltd. to Buy with a price target of 2600.0 on 26 Nov, 2025.

Mankind Pharma Ltd.

17 Sep 2025

2166.80

0.83%

Mankind Pharma collaborates with OpenAI to build agile supply chains, research

Business Line

Mankind will integrate OpenAI Enterprise across multiple functions, including field force enablement, digital marketing, research and development (R&D), manufacturing, and medical affairs

Number of FII/FPI investors decreased from 648 to 627 in Sep 2025 qtr

Mankind Pharma Ltd.

08 Sep 2025

2166.80

0.83%

Mankind Pharma gets CDSCO nod for Phase 1 trials for novel autoimmune drug

Business Standard

Mankind Pharma has received CDSCO approval to initiate Phase 1 trials of MKP11093, a novel JAK-1 inhibitor for autoimmune disorders, as part of its expanding R&D pipeline

Mankind Pharma Ltd. is trading below all available SMAs

CDSCO clears Mankind's Phase 1 trial for autoimmune disorder molecule

Business Standard | 08 Sep 2025

Mankind Pharma Ltd.

09 Aug 2025

2166.80

0.83%

Mankind Pharma Confident GLP-1 Won't Dent Anti-Diabetic Portfolio Growth

NDTV Profit

Even if shifts occur within the anti-diabetes segment, such as therapies moving from the top to the bottom of the market pyramid, Mankind expects to remain stable.

Mankind Pharma Ltd. has an average target of 2700.00 from 2 brokers.

Mankind Pharma Ltd.

01 Aug 2025

2166.80

0.83%

Mankind Pharma Results Earnings Call for Q1FY26

Conference Call with Mankind Pharma Management and Analysts on Q1FY26 Performance and Outlook. Listen to the full earnings transcript.

Near 52W Low of ₹2115.10

Mankind Pharma News and Updates

Keep track of all breaking news on Mankind Pharma from all sources in a single place.